FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Read more
FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Read more
Aumenta Solutions, MSI, Jelurida Partner for Blockchain-Based Port Infrastructure Maintenance Platform Read more